GO
Loading...

Medicine

More

  • March 23- MEI Pharma lost more than two-thirds of its market value on Monday after the company's cancer drug failed to meet the main goal in a mid-stage study. "The risk profile for pracinostat has significantly increased and one potential scenario is the discontinuation of the drug's development," Roth Capital's Joseph Pantginis said, slashing his price...

  • Biogen Idec shortens its name to Biogen Monday, 23 Mar 2015 | 8:54 AM ET

    NEW YORK— Biogen Idec Inc. is shortening its name to just Biogen as of Monday. The company was created 12 years ago through the merger of Biogen with IDEC Pharmaceuticals and has since focused on three core areas, including neurology, immunology and hematology. Biogen, based in Cambridge, Massachusetts, makes blockbuster multiple sclerosis treatments Avonex...

  • March 23- MEI Pharma was set to lose more than half its market value on Monday after the company's cancer drug failed to meet the main goal in a mid-stage study. MEI Pharma's shares were down 64 percent at $2.28 in premarket trading. MEI Pharma said there was a higher rate of discontinuations for the combination compared with those taking azacitidine alone due to...

  • March 23- MEI Pharma says its cancer drug failed to meet the main goal in a mid-stage study. The drug, pracinostat, in combination with chemotherapy drug azacitidine showed no difference in complete remission in previously untreated patients with myelodysplastic syndrome- a type of blood cancer- against azacitidine alone. Complete remission implies the...

  • Promising Alzheimer's drug   Friday, 20 Mar 2015 | 1:01 PM ET
    Man with Alzheimer

    Biogen will move its Alzheimer's drug quickly into phase 3 studies, jumping over the middle stage, reports CNBC's Meg Tirrell.

  • NEW YORK— Shares of Irish drug developer Prothena surged Friday after the company reported promising results from an early-stage study of a drug designed to treat Parkinson's disease. Prothena said the study showed the drug, PRX002, was safe, without serious side effects, and that it reduced levels of a protein that is believed it be associated with the disease.

  • March 20- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with...

  • Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients. In December, the biotechnology company said the developing drug aducanumab reduced a type of plaque in the brain believed to play a key role in the disease and slowed clinical...

  • March 20- An experimental drug from Biogen Idec became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with expensive...

  • March 19- GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough to be approved in adults with asthma, but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. Glaxo licensed the product from...

  • The FDA is not required to follow the recommendations of its experts, though it often does. Breo Ellipta is already approved in the U.S. for a type of chronic lung disease, but Glaxo is hoping to expand the drug's use to the much larger patient population of roughly 37 million Americans with asthma. In 2010, FDA required manufacturers of LABA-steroid combination...

  • New Alzheimer's drug data   Thursday, 19 Mar 2015 | 1:02 PM ET
    New Alzheimer's drug data

    Biogen is set to release full data on Friday of its Alzheimer's drug, reports CNBC's Meg Tirrell.

  • Amicus to seek Fabry disease drug approval Thursday, 19 Mar 2015 | 12:46 PM ET

    CRANBURY, N.J.— Amicus Therapeutics plans to file for accelerated approval of its experimental treatment for a rare, inherited disease following meetings with regulators in the U.S. and Europe. In the U.S., the company plans to file for approval of the drug, called migalastat, with the Food and Drug Administration in the second half of the year, while it plans on...

  • LOS ANGELES— A much-hailed law that restricted the opening of new stand-alone fast-food restaurants in one of the poorest sections of Los Angeles did not curb obesity or improve diets, a new study found. The research by the Rand Corp. think tank found that obesity rates in South Los Angeles continued to rise after passage of the law. "It's not just about limiting...

  • Charity attacks Gilead over hepatitis C drug restrictions Wednesday, 18 Mar 2015 | 4:17 PM ET

    March 18- Charity Medecins Sans Frontieres has accused U.S. drugmaker Gilead Sciences Inc of restricting access to its breakthrough hepatitis C drug Sovaldi in developing countries as it tries to protect profit margin in wealthier nations. "We're seeing Gilead trying everything it can to squeeze every last drop of profit out of some middle-income and...

  • New threat to medical marijuana may surprise you Wednesday, 18 Mar 2015 | 11:48 AM ET
    An employee packages a patient's cannabis at a medical cannabis center in Lakewood, Colorado.

    Medical marijuana sales growth in Colorado has dipped since recreational pot has been legalized in the state.

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • March 17- Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study. Breast cancer is the second leading cause of cancer-related death among women, according to the U.S. National Cancer Institute. This year, an estimated 207,000 women will be diagnosed with the...

  • March 17- Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study. Breast cancer is the second leading cause of cancer-related death among women, according to the U.S. National Cancer Institute. This year, an estimated 207,000 women will be diagnosed with the...

  • March 17- Esperion Therapeutics Inc said its experimental drug lowered LDL or "bad" cholesterol levels in patients who were already on statins, the current standard of care. Needham& Co analyst Chad Messer said he expects the drug to be adopted faster as an additional therapy to statins rather than replacing statins altogether. There are about 35 million...